[go: up one dir, main page]

AU2001259085A1 - Treatment of ocular neovascularization and related diseases - Google Patents

Treatment of ocular neovascularization and related diseases

Info

Publication number
AU2001259085A1
AU2001259085A1 AU2001259085A AU5908501A AU2001259085A1 AU 2001259085 A1 AU2001259085 A1 AU 2001259085A1 AU 2001259085 A AU2001259085 A AU 2001259085A AU 5908501 A AU5908501 A AU 5908501A AU 2001259085 A1 AU2001259085 A1 AU 2001259085A1
Authority
AU
Australia
Prior art keywords
treatment
related diseases
ocular neovascularization
neovascularization
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259085A
Inventor
Robert L. Gendron
Helene Paradis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Research Foundation
Original Assignee
Childrens Hospital Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Research Foundation filed Critical Childrens Hospital Research Foundation
Publication of AU2001259085A1 publication Critical patent/AU2001259085A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001259085A 2000-04-17 2001-04-17 Treatment of ocular neovascularization and related diseases Abandoned AU2001259085A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19797700P 2000-04-17 2000-04-17
US60197977 2000-04-17
PCT/US2001/012548 WO2001079506A2 (en) 2000-04-17 2001-04-17 Treatment of ocular neovascularization and related diseases

Publications (1)

Publication Number Publication Date
AU2001259085A1 true AU2001259085A1 (en) 2001-10-30

Family

ID=22731498

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259085A Abandoned AU2001259085A1 (en) 2000-04-17 2001-04-17 Treatment of ocular neovascularization and related diseases

Country Status (3)

Country Link
US (1) US6696415B2 (en)
AU (1) AU2001259085A1 (en)
WO (1) WO2001079506A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016614A1 (en) * 2000-08-18 2002-02-28 Merck Patent Gmbh Identification of a human n-terminal acetyltransferase gene
US7678065B2 (en) * 2001-05-02 2010-03-16 Glaukos Corporation Implant with intraocular pressure sensor for glaucoma treatment
AU2002305400A1 (en) * 2001-05-03 2002-11-18 Glaukos Corporation Medical device and methods of use for glaucoma treatment
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
WO2005113017A2 (en) * 2004-04-22 2005-12-01 Florida Atlantic University Gfap-based gene therapy for treatment of retinal diseases
US20050244512A1 (en) * 2004-05-01 2005-11-03 Holekamp Nancy M Ophthalmic fluid and method of delivering same
US8480006B2 (en) * 2006-09-08 2013-07-09 Ventech, Llc Vehicle supplemental heating system
EP3785683B1 (en) 2009-05-18 2023-11-01 Dose Medical Corporation Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP2755549A1 (en) 2011-09-13 2014-07-23 Dose Medical Corporation Intraocular physiological sensor
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents

Also Published As

Publication number Publication date
US6696415B2 (en) 2004-02-24
WO2001079506A2 (en) 2001-10-25
WO2001079506A3 (en) 2002-03-14
US20020137678A1 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
AU2001280440A1 (en) Treatment of human herpesviruses using hyperthermia
EP1392292A4 (en) Pyranoindazoles and their use for the treatment of glaucoma
AUPQ415899A0 (en) Compositions for and methods of treatment of allergic diseases
AU2001259085A1 (en) Treatment of ocular neovascularization and related diseases
AU2002240463A1 (en) Use of endostatin in the treatment of ocular neovascularization
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
AUPQ622600A0 (en) Treatment and/or prevention of ocular pain
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU2002227935A1 (en) Optical stimulation of the human eye
AU6887101A (en) Copolymers and methods of treating prion-related diseases
AUPQ344799A0 (en) Treatment of respiratory diseases and infections
AU7106300A (en) Treatment of skin disorders
ZA200400210B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
AU2000275035A1 (en) Therapeutic and prophylactic drugs of myopia
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2001258575A1 (en) Treatment of cancer and neurological diseases
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002361516A1 (en) Ophthalmic rofecoxib suspension for the treatment of ocular pain and inflammation
AU1405001A (en) Treatment of diseases
AU4114301A (en) Treatment of ocular hypertension and glaucoma
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU2908501A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
AU2001239005A1 (en) Treatment and/or prevention of ocular pain
AU2002365654A1 (en) Treatment of diseases via the skin
AU2001230589A1 (en) Therapeutic and/or preventive agents for optic nerve diseases and retinal diseases